AAA
ELVN icon

Affinity Asset Advisors’s Enliven Therapeutics ELVN Stock Holding History

Affinity Asset Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4M Sell
500,000
-86,904
-15% -$3.69M 1.15% 27
2026
Q1 		$23M Buy
+586,904
New +$16.3M 1.19% 28
2025
Q4 		– Sell
-400,000
Closed -$8.19M – 100
2025
Q3 		$8.19M Hold
400,000
– – 0.71% 38
2025
Q2 		$8.02M Buy
+400,000
New +$7.57M 1.1% 28

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Affinity Asset Advisors's ELVN Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Enliven Therapeutics (ELVN) stake by 15% in Q2 2026, selling an estimated $3.69M and leaving 500,000 shares worth $25.4M. The position accounts for 1.15% of the portfolio, ranked #27.

Affinity Asset Advisors first reported a position in ELVN in Q2 2025 and has held it in 4 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Affinity Asset Advisors held 500,000 shares of Enliven Therapeutics worth $25.4M as of Q2 2026.
  • Affinity Asset Advisors sold 86,904 Enliven Therapeutics shares in Q2 2026, an estimated $3.69M.
  • Enliven Therapeutics made up 1.15% of Affinity Asset Advisors's portfolio in Q2 2026, its #27 holding.
  • Affinity Asset Advisors first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.